Form 4: Boston Scientific Executive Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, exercised stock options and subsequently sold 50,000 shares of common stock on July 1, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp (BSX), engaged in transactions involving the company's common stock on July 1, 2025.
• He exercised stock options to acquire 50,000 shares of common stock at an exercise price of $26.15 per share.
• Concurrently, he sold 50,000 shares of common stock at a weighted average price of $106.9663 per share, with individual sales ranging from $106.66 to $107.37.
• These transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
• Following these transactions, Fitzgerald directly beneficially owns 178,342 shares of common stock and 200,000 stock options.
• An additional 5,234 shares are indirectly held by his child, though Fitzgerald disclaims beneficial ownership of these shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While an executive selling shares can sometimes be viewed negatively, the fact that it was done under a pre-established 10b5-1 plan mitigates concerns about opportunistic trading. The significant profit from the option exercise and sale is a positive for the executive, and the transaction itself is a routine part of executive compensation and liquidity management.

Positives

• The executive exercised options at a significantly lower price ($26.15) and sold shares at a much higher price (average $106.9663), indicating a profitable transaction for the individual.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, which demonstrates a structured approach to insider trading and can mitigate concerns about opportunistic trading.

Negatives

• The sale of 50,000 shares by a senior executive could be interpreted by some investors as a liquidity event or, by others, as a lack of confidence, although it is a common practice for executives to diversify their holdings.

Related Party Transactions

• Joseph Michael Fitzgerald disclaims beneficial ownership of 5,234 shares of common stock held by his child.

Stakeholder Impact

• Shareholders: The sale of shares by a senior executive could be viewed as a routine liquidity event or, by some, as a signal, though the 10b5-1 plan mitigates negative interpretations. The transaction itself does not directly impact company operations or financial health.

Key Dates

Keywords

Boston Scientific, BSX, Joseph Michael Fitzgerald, SEC Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1 Plan, Executive Compensation, Cardiology